Japan Panel Clears 1st Oral SMA Drug, 2 Migraine Meds, RNAi Therapy and More

May 27, 2021
A key health ministry advisory panel on May 26 gave the blessing to a throng of new medicines including Chugai Pharmaceutical’s risdiplam, which would be the first oral treatment for spinal muscular atrophy (SMA). If all goes well, they will...read more